University Of Mississippi
‘I’ve never been treated so well’: Same-day cancer screening program helps reduce barriers
While on-site at a same-day cancer screening program he helped to implement, Timothy Craig Allen, MD, JD, FCAP, came across a crying woman.
Economic burden of HF climbing, preventive guidance lacking, but tools available
HF is a growing economic burden in the U.S., with 1 million new cases projected to surface in 2021; however, there is a paucity of guidance on HF prevention, a speaker reported.
In stage 1 hypertension, medication feasible if BP goal not met after lifestyle changes
In an update to the 2017 hypertension guideline, the American Heart Association recommended lifestyle changes for patients with slightly elevated BP, adding medication if necessary after 6 months.
HF readmission rates rose from 2010 to 2017
Despite the introduction of financial penalties for U.S. hospitals with high HF readmission rates, HF readmission rates rose from 2010 to 2017, according to a new analysis in Circulation: Heart Failure.
Empagliflozin improves outcomes in HFrEF, regardless of baseline health status
The benefits of empagliflozin compared with placebo for HF with reduced ejection fraction occurred regardless of health status at baseline, according to a secondary analysis of the EMPEROR-Reduced trial.
Meta-analyses: Mitral contour system delivers good clinical, patient-centered results
According to two meta-analyses, a mitral contour system for functional mitral regurgitation conferred not only good clinical results, but also positive patient-based outcomes.
Smoking increases CHD risk among Black adults
Among Black adults, smoking was associated with elevated risk for CHD, according to research published in the Journal of the American Heart Association.
Klisyri superior to placebo for treatment of actinic keratoses in randomized studies
Klisyri, an FDA-approved Src kinase signaling inhibitor, was superior to placebo for the treatment of actinic keratoses, according to findings from two double-blind randomized trials published in The New England Journal of Medicine.